The LA5C is a subset of the LA2K population, consisting of 500 subject: 200 healthy controls, 100 schizophrenia patients, 100 bipolar patients, and 100 ADHD patients. See here for the LA2K manual: LA2k_manual.
The participants, ages 21-50, were recruited by community advertisements from the Los Angeles area and completed extensive neuropsychogical testing, in addition to fMRI scanning. To be included individuals had to be either “White, Not of Hispanic or Latino Origin” or “Hispanic or Latino, of Any Race” following NIH designations of racial and ethnic minority groups, and have completed at least 8 years of education (other racial and ethnic minority groups were excluded because this was thought to increase risk of confounding planned genetic studies). For participants who spoke both English and Spanish, language for testing was determined by a verbal fluency test. Participants were screened for neurological disease, history of head injury with loss of consciousness or cognitive sequelae, use of psychoactive medications, substance dependence within past 6 months, history of major mental illness or ADHD, and current mood or anxiety disorder. Self-reported history of psychopathology was verified with the SCID-IV (First, Spitzer, Gibbon, & Williams, 1995). Urinalysis was used to screen for drugs of abuse (cannabis, amphetamine, opioids, cocaine, benzodiazepines) on the day of testing and excluded if results were positive.
A portion of this large sample took part in two separate fMRI sessions, which each included one-hour of behavioral testing and a one-hour scan on the same day. Participants were recruited from the parent study to participate in the fMRI portion if they successfully completed all previous testing sessions, and did not meet the following additional exclusion criteria: history of significant medical illness, contraindications for MRI (including pregnancy), any mood-altering medication on scan day (based on self-report), vision that was insufficient to see task stimuli, and left-handedness.
After receiving a thorough explanation, all participants gave written informed consent according to the procedures approved by the University of California Los Angeles Institutional Review Board.
For more information on the LA5C please contact:
Eliza Congdon, Ph.D. email email@example.com
Katie Karlsgodt, Ph.D. email firstname.lastname@example.org
Russell Poldrack, Ph.D. email email@example.com
Fred Sabb, Ph.D. email firstname.lastname@example.org
link to LA5C manual
overall study design (scan A, scan B, etc)
Preprocessing and Quality Control
Requesting and Analyzing Data
Link back to HTAC page.